Even at low-density lipoprotein cholesterol (LDL-C) goal, patients with cardiometabolic
abnormalities remain at high risk of cardiovascular events. This paper aims (i) to critically …

Widely varied chemicals—including certain herbicides, plasticizers, drugs, and natural
products—induce peroxisome proliferation in rodent liver and other tissues. This …

Abstract Background Plasma apolipoprotein B (apoB) is a composite measure of all apoB-
containing lipoproteins causing atherosclerotic cardiovascular disease; however, it is …

In a randomized, double-blind five-year trial, we tested the efficacy of simultaneously
elevating serum levels of high-density lipoprotein (HDL) cholesterol and lowering levels of …

Deaths from ischæmic heart-disease in 18 developed countries are not strongly associated
with health-service factors such as doctor and nurse density. There is a negative association …

Considerable evidence supports the association between insulin resistance and vascular
disease, and this has led to wide acceptance of the clustering of hyperlipidemia, glucose …

In the Helsinki Heart Study, a randomized five-year, double-blind trial, a 34% reduction in
the incidence of coronary heart disease (CHD) was observed in dyslipidemic men treated …

Although statin therapy represents a cornerstone of cardiovascular disease (CVD)
prevention, a major residual CVD risk (60–70% of total relative risk) remains, attributable to …

Cardiovascular disease (CVD) is the major cause of death in the US and in most Western
countries. Despite the recent sharp decline in the death rate from CVD, 1 it still accounts for …

Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced
Hepatocarcinogenesis - J. Ashby, A. Brady, CR Elcombe, BM Elliott, J. Ishmael, J. Odum, JD …